J. A. Sparano

570 total citations
24 papers, 447 citations indexed

About

J. A. Sparano is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J. A. Sparano has authored 24 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 9 papers in Cancer Research and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J. A. Sparano's work include Cancer Treatment and Pharmacology (11 papers), Breast Cancer Treatment Studies (8 papers) and Advanced Breast Cancer Therapies (6 papers). J. A. Sparano is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Breast Cancer Treatment Studies (8 papers) and Advanced Breast Cancer Therapies (6 papers). J. A. Sparano collaborates with scholars based in United States, Poland and Italy. J. A. Sparano's co-authors include EP Winer, George W. Sledge, Eric K. Rowinsky, Donna Neuberg, N. J. Robert, Lori J. Goldstein, Worta McCaskill‐Stevens, William J. Gradishar, Kathy D. Miller and Lynn M. Schuchter and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

J. A. Sparano

24 papers receiving 431 citations

Peers

J. A. Sparano
Felipe G. Gercovich Argentina
Matthew Volm United States
Samuel G.W. Ow Singapore
Kathrin Glatz Switzerland
D. Paraïso France
Stephanie Roberson United States
T. Rinda Soong United States
Geetha Menezes United States
Paweł Teterycz Poland
Paola Ghione United States
Felipe G. Gercovich Argentina
J. A. Sparano
Citations per year, relative to J. A. Sparano J. A. Sparano (= 1×) peers Felipe G. Gercovich

Countries citing papers authored by J. A. Sparano

Since Specialization
Citations

This map shows the geographic impact of J. A. Sparano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. A. Sparano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. A. Sparano more than expected).

Fields of papers citing papers by J. A. Sparano

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. A. Sparano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. A. Sparano. The network helps show where J. A. Sparano may publish in the future.

Co-authorship network of co-authors of J. A. Sparano

This figure shows the co-authorship network connecting the top 25 collaborators of J. A. Sparano. A scholar is included among the top collaborators of J. A. Sparano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. A. Sparano. J. A. Sparano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Schneider, Bryan P., Vered Stearns, Silvana Martino, et al.. (2011). Relationship between taxane-induced neuropathy and clinical outcomes after adjuvant chemotherapy.. Journal of Clinical Oncology. 29(27_suppl). 270–270. 1 indexed citations
3.
Miller, Kurt W., Milan Radovich, Bradley A. Hancock, et al.. (2011). Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103.. Journal of Clinical Oncology. 29(15_suppl). 1000–1000. 34 indexed citations
4.
Sparano, J. A., James F. Caravelli, Swati Patil, et al.. (2010). Phase II trial of saracatinib in patients (pts) with ER/PR-negative metastatic breast cancer (MBC).. Journal of Clinical Oncology. 28(15_suppl). 1086–1086. 4 indexed citations
5.
Sparano, J. A., Vered Stearns, Silvana Martino, et al.. (2009). Black Race Is Associated with a Worse Outcome in Patients with Hormone Receptor Positive, HER2-Normal Breast Cancer Treated with Adjuvant Chemohormonal Therapy.. Cancer Research. 69(24_Supplement). 37–37. 2 indexed citations
6.
Conté, Pierfranco, Henri Roché, Edith A. Perez, et al.. (2009). Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large phase III studies.. Cancer Research. 69(2_Supplement). 6114–6114. 11 indexed citations
7.
Sparano, J. A., Robert P. Gray, Lori J. Goldstein, et al.. (2009). Gene Expression Profiling of Phenotypically-Defined Hormone-Receptor Positive Breast Cancer: Evidence for Increased Transcriptional Activity of the Insulin Growth Factor Receptor Pathway and Other Pathways.. Cancer Research. 69(24_Supplement). 5165–5165. 2 indexed citations
8.
Levine, A. M., et al.. (2008). Efficacy and toxicity of concurrent rituximab plus infusional EPOCH in HIV-associated lymphoma: AIDS Malignancy Consortium Trial 034. Journal of Clinical Oncology. 26(15_suppl). 8527–8527. 8 indexed citations
9.
Goldstein, Lori J., Robert J. Gray, Roberto Bugarini, et al.. (2008). Predictive utility of progesterone receptor (PR) and multigene expression in identifying benefit from adjuvant doxorubicin plus cyclophosphamide (AC) or docetaxel (AT) in intergroup trial E2197. Journal of Clinical Oncology. 26(15_suppl). 557–557. 1 indexed citations
10.
Badve, Sunil, Frederick L. Baehner, Robert J. Gray, et al.. (2007). Concordance of local and central laboratory hormone and HER2 receptor status in ECOG 2197. Journal of Clinical Oncology. 25(18_suppl). 21022–21022. 2 indexed citations
11.
Sparano, J. A., Simona Di Martino, Veronica Jones, et al.. (2007). Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199. Journal of Clinical Oncology. 25(18_suppl). 516–516. 27 indexed citations
12.
Miller, Kathy D., William J. Gradishar, Lynn M. Schuchter, et al.. (2002). A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Annals of Oncology. 13(8). 1220–1224. 44 indexed citations
13.
Sparano, J. A.. (2001). Cardiac toxicity of trastuzumab (Herceptin): Implications for the design of adjuvant trials. Seminars in Oncology. 28(1 Suppl 3). 20–27. 72 indexed citations
14.
Sparano, J. A. & EP Winer. (2001). Liposomal anthracyclines for breast cancer. Seminars in Oncology. 28(4 Suppl 12). 32–40. 42 indexed citations
15.
16.
Sparano, J. A., Xiao Hu, Peter H. Wiernik, et al.. (1997). Opportunistic Infection and Immunologic Function in Patients With Human Immunodeficiency Virus-Associated Non-Hodgkin's Lymphoma Treated With Chemotherapy. JNCI Journal of the National Cancer Institute. 89(4). 301–307. 28 indexed citations
17.
Sledge, George W., N. J. Robert, J. A. Sparano, et al.. (1995). Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer.. PubMed. 22(3 Suppl 6). 105–8. 34 indexed citations
18.
Sparano, J. A.. (1995). Treatment of AIDS-related lymphomas.. PubMed. 7(5). 442–9. 15 indexed citations
19.
Sledge, George W., N. J. Robert, J. A. Sparano, et al.. (1994). Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.. PubMed. 21(5 Suppl 8). 15–8. 43 indexed citations
20.
Sparano, J. A., et al.. (1992). Cerebral infection complicating systemic aspergillosis in acute leukemia: clinical and radiographic presentation. Journal of Neuro-Oncology. 13(1). 91–100. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Felipe G. Gercovich Breakdown of academic impact, for papers by Matthew Volm Breakdown of academic impact, for papers by Samuel G.W. Ow Breakdown of academic impact, for papers by Kathrin Glatz Breakdown of academic impact, for papers by D. Paraïso Breakdown of academic impact, for papers by Stephanie Roberson Breakdown of academic impact, for papers by T. Rinda Soong Breakdown of academic impact, for papers by Geetha Menezes Breakdown of academic impact, for papers by Paweł Teterycz Breakdown of academic impact, for papers by Paola Ghione
Rankless by CCL
2026